A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

Antibody-directed enzyme prodrug therapy is a targeted therapy in which a prodrug is activated selectively at the tumour site by an enzyme, which has been targeted to the tumour by an antibody (antibody-enzyme conjugate). Previous clinical trials have shown evidence of tumour response, however, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Francis, R J, Sharma, S K, Springer, C, Green, A J, Hope-Stone, L D, Sena, L, Martin, J, Adamson, K L, Robbins, A, Gumbrell, L, O'Malley, D, Tsiompanou, E, Shahbakhti, H, Webley, S, Hochhauser, D, Hilson, A J, Blakey, D, Begent, R H J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364249/
https://www.ncbi.nlm.nih.gov/pubmed/12237768
http://dx.doi.org/10.1038/sj.bjc.6600517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364249/
https://www.ncbi.nlm.nih.gov/pubmed/12237768
http://dx.doi.org/10.1038/sj.bjc.6600517

Ejemplares similares